Song K, Wang J, Huang D
J Natl Cancer Cent. 2024; 3(4):273-278.
PMID: 39036667
PMC: 11256611.
DOI: 10.1016/j.jncc.2023.09.001.
Truskowski K, Amend S, Pienta K
Cancer Metastasis Rev. 2023; 42(1):37-47.
PMID: 36598661
PMC: 10014758.
DOI: 10.1007/s10555-022-10073-z.
Hurson A, Abubakar M, Hamilton A, Conway K, Hoadley K, Love M
NPJ Breast Cancer. 2022; 8(1):74.
PMID: 35701440
PMC: 9198049.
DOI: 10.1038/s41523-022-00437-7.
Ei Z, Choochuay K, Tubsuwan A, Pinkaew D, Suksomtip M, Vinayanuwattikun C
Sci Rep. 2021; 11(1):22448.
PMID: 34789798
PMC: 8599848.
DOI: 10.1038/s41598-021-01540-8.
Balahura L, Dinescu S, Balas M, Cernencu A, Lungu A, Vlasceanu G
Pharmaceutics. 2021; 13(8).
PMID: 34452150
PMC: 8400202.
DOI: 10.3390/pharmaceutics13081189.
Prognostic Value of the Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing.
Bai H, Yu J, Jia S, Liu X, Liang X, Li H
Cancer Manag Res. 2021; 13:3303-3316.
PMID: 33889023
PMC: 8057094.
DOI: 10.2147/CMAR.S298729.
The complexity of p53-mediated metabolic regulation in tumor suppression.
Liu Y, Gu W
Semin Cancer Biol. 2021; 85:4-32.
PMID: 33785447
PMC: 8473587.
DOI: 10.1016/j.semcancer.2021.03.010.
Analysis of TP53 gene and particular infrastructural alterations in invasive ductal mammary carcinoma.
Mihalcea C, Morosanu A, Murarasu D, Puiu L, Cinca S, Voinea S
Rom J Morphol Embryol. 2021; 61(2):441-447.
PMID: 33544795
PMC: 7864295.
DOI: 10.47162/RJME.61.2.13.
Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.
Kadioglu O, Saeed M, Mahmoud N, Azawi S, Mrasek K, Liehr T
Arch Toxicol. 2021; 95(3):959-974.
PMID: 33515271
PMC: 7904745.
DOI: 10.1007/s00204-021-02979-4.
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A, Padellan M, Marchenko N
Breast Cancer Res. 2020; 22(1):133.
PMID: 33267874
PMC: 7709447.
DOI: 10.1186/s13058-020-01370-y.
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.
Shahbandi A, Nguyen H, Jackson J
Trends Cancer. 2020; 6(2):98-110.
PMID: 32061310
PMC: 7931175.
DOI: 10.1016/j.trecan.2020.01.007.
Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53.
Ghaleb A, Yallowitz A, Marchenko N
Commun Biol. 2019; 2:436.
PMID: 31799437
PMC: 6881331.
DOI: 10.1038/s42003-019-0669-y.
p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant.
Humpton T, Hock A, Maddocks O, Vousden K
Cancer Metab. 2018; 6:18.
PMID: 30524726
PMC: 6276204.
DOI: 10.1186/s40170-018-0191-6.
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
Ungerleider N, Rao S, Shahbandi A, Yee D, Niu T, Frey W
Breast Cancer Res. 2018; 20(1):115.
PMID: 30285883
PMC: 6167800.
DOI: 10.1186/s13058-018-1044-5.
The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?.
Moulder D, Hatoum D, Tay E, Lin Y, McGowan E
Cancers (Basel). 2018; 10(6).
PMID: 29890631
PMC: 6024909.
DOI: 10.3390/cancers10060189.
Control of metabolism by p53 - Cancer and beyond.
Labuschagne C, Zani F, Vousden K
Biochim Biophys Acta Rev Cancer. 2018; 1870(1):32-42.
PMID: 29883595
PMC: 6102416.
DOI: 10.1016/j.bbcan.2018.06.001.
Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.
van Beek E, Hernandez J, Goldman D, Davis J, McLaughlin K, Ripley R
Ann Surg Oncol. 2018; 25(7):2027-2033.
PMID: 29725898
PMC: 6644702.
DOI: 10.1245/s10434-018-6502-x.
Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
Constantinou C, Papadopoulos S, Karyda E, Alexopoulos A, Agnanti N, Batistatou A
In Vivo. 2018; 32(2):303-311.
PMID: 29475913
PMC: 5905198.
DOI: 10.21873/invivo.11238.
Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition.
Sakhawat A, Liu Y, Ma L, Muhammad T, Wang S, Zhang L
J Cancer. 2017; 8(8):1425-1432.
PMID: 28638457
PMC: 5479248.
DOI: 10.7150/jca.18371.
Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.
Taylor N, Nikolaishvili-Feinberg N, Midkiff B, Conway K, Millikan R, Geradts J
Appl Immunohistochem Mol Morphol. 2015; 24(6):398-404.
PMID: 26200835
PMC: 4716889.
DOI: 10.1097/PAI.0000000000000207.